UNI-MB - logo
UMNIK - logo
 
E-resources
Peer reviewed Open access
  • Tumor-infiltrating lymphocy...
    Loi, Sherene

    Oncoimmunology, 07/2013, Volume: 2, Issue: 7
    Journal Article

    By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes.